Literature DB >> 25265921

Value of diffusion-weighted magnetic resonance imaging on the follow-up of nasopharyngeal carcinoma after radiotherapy.

Ji-Fei Xu1, Xing-Wang Wu2, Wan-Qin Wang2, Ling-Ling Kong1, Li-Ming Wu1, Fan Wang1.   

Abstract

PURPOSE: To explore the value of diffusion-weighted imaging (DWI) and magnetic resonance imaging (MRI) on the follow-up of nasopharyngeal carcinoma (NPC) after radiotherapy.
MATERIAL AND METHODS: Eighty-three NPC patients after radiotherapy were divided into two groups: 4 cases of residual tumor and 33 cases of non-residual within 6 months, the cases of recurrent and non-recurrent were 5 and 41 over 6 months, respectively. MRI and DWI imaging of these cases were closely analyzed, and the apparent diffusion coefficient (ADC) of the nasopharyngeal residual mass and nasopharyngeal wall thickening, skull base destruction and lateral pterygoid muscle were measured.
RESULTS: The ADC of the lateral pterygoid muscle was (1.501 ± 0.069) × 10<formula>^{ - 3}</formula> mm<formula>^{2}</formula>/s in 83 cases. The ADCs of the non-residual group, residual group, non-recurrent group and recurrent group were (1.843 ± 0.133.4) × 10<formula>^{ - 3}</formula> mm<formula>^{2}</formula>/s, (1.097 ± 0.183) × 10<formula>^{ - 3}</formula> mm<formula>^{2}</formula>/s, (1.884 ± 0.134) × 10<formula>^{ - 3}</formula> mm<formula>^{2}</formula>/s and (0.787 ± 0.067) × 10<formula>^{ - 3}</formula> mm<formula>^{2}</formula>/s respectively.The ADCs of the residual group and recurrent group were lower than that of the lateral pterygoid muscle, while the ADCs of the non-residual group and non-recurrent group were higher than that of the lateral pterygoid muscle.The differences were statistically significant (P < 0.05).
CONCLUSION: DWI can provide qualitative and quantitative information about the tumor cellular level; it can also identify residual, local fibrosis and recurrence after NPC radiotherapy sensitively and accurately by measuring the ADC of the region of interest.

Entities:  

Keywords:  Magnetic resonance imaging; diffusion; nasopharyngeal neoplasms; radiotherapy

Mesh:

Year:  2014        PMID: 25265921     DOI: 10.3233/XST-140448

Source DB:  PubMed          Journal:  J Xray Sci Technol        ISSN: 0895-3996            Impact factor:   1.535


  6 in total

1.  Diffusion-Weighted Imaging of Nasopharyngeal Carcinoma: Can Pretreatment DWI Predict Local Failure Based on Long-Term Outcome?

Authors:  B K H Law; A D King; K S Bhatia; A T Ahuja; M K M Kam; B B Ma; Q Y Ai; F K F Mo; J Yuan; D K W Yeung
Journal:  AJNR Am J Neuroradiol       Date:  2016-05-05       Impact factor: 3.825

2.  Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases.

Authors:  Yuan Zhang; Xu Liu; Yun Zhang; Wen-Fei Li; Lei Chen; Yan-Ping Mao; Jing-Xian Shen; Fan Zhang; Hao Peng; Qing Liu; Ying Sun; Jun Ma
Journal:  Sci Rep       Date:  2015-07-17       Impact factor: 4.379

3.  Application of Artificial Intelligence in Radiotherapy of Nasopharyngeal Carcinoma with Magnetic Resonance Imaging.

Authors:  Wanlu Zhao; Desheng Zhang; Xinjian Mao
Journal:  J Healthc Eng       Date:  2022-02-02       Impact factor: 2.682

4.  Diffusion-kurtosis imaging predicts early radiotherapy response in nasopharyngeal carcinoma patients.

Authors:  Gang Wu; Meng-Meng Li; Feng Chen; Shao-Ming Lin; Kai Yang; Ying-Man Zhao; Xiao-Lei Zhu; Wei-Yuan Huang; Jian-Jun Li
Journal:  Oncotarget       Date:  2017-08-02

5.  Diagnostic value of diffusion-weighted magnetic resonance imaging for local and skull base recurrence of nasopharyngeal carcinoma after radiotherapy.

Authors:  Chen Wang; Lidong Liu; Shaolv Lai; Danke Su; Younan Liu; Guanqiao Jin; Xuna Zhu; Ningbin Luo
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

6.  Correlation of PET-CT, MRI and histopathology findings in the follow-up of patients with nasopharyngeal cancer.

Authors:  Semih Ak; Caner Kiliç; Samet Özlügedik
Journal:  Braz J Otorhinolaryngol       Date:  2020-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.